Globus IPO Bid Is Good News For Spine Industry
This article was originally published in Start Up
Executive Summary
Globus Medical filed for an initial public offering of stock in March, making it the first spine company to test the public markets since TranS1 raised $86 million in its own IPO at the tail end of 2007.
You may also be interested in...
Globus Prepared for Trek with $110m from Clarus-led Group
Clarus Ventures placed an unusually big bet for the orthopedics industry by leading a syndicate of private equity investors in a $110 million Series E round in Globus Medical Inc. But the four-year-old company is well ahead of its peers with more than $100 million in sales and a line of fusion products on the market. The company faces the challenge of introducing a new line of non-fusion and biomaterial products if it hopes to grow into the industry leader its investors expects it to be.
Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.
FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.